Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 5 minute read Pharma Industry News Cytokinetics stock skyrockets 40% as ESC 2025 data positions aficamten to challenge beta-blockers in HCM Cytokinetics shares surged 40% after new ESC 2025 data showed aficamten's superiority to metoprolol in HCM. Is FDA approval now inevitable? byPallavi MadhirajuSeptember 3, 2025